Premium
Cellular and humoral response after MRNA‐1273 SARS‐CoV‐2 vaccine in kidney transplant recipients
Author(s) -
Cucchiari David,
Egri Natalia,
Bodro Marta,
Herrera Sabina,
Del RiscoZevallos Jimena,
CasalsUrquiza Joaquim,
Cofan Frederic,
Moreno Asunción,
Rovira Jordi,
BaManeus Elisenda,
RamirezBajo Maria J.,
VenturaAguiar Pedro,
PérezOlmos Anna,
GarciaPascual Marta,
Pascal Mariona,
Vilella Anna,
Trilla Antoni,
Ríos José,
Palou Eduard,
Juan Manel,
Bayés Beatriu,
Diekmann Fritz
Publication year - 2021
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/ajt.16701
Subject(s) - elispot , medicine , immunology , seroconversion , vaccination , humoral immunity , immune system , kidney transplantation , antibody , cellular immunity , kidney , virology , t cell
According to preliminary data, seroconversion after mRNA SARS‐CoV‐2 vaccination might be unsatisfactory in Kidney Transplant Recipients (KTRs). However, it is unknown if seronegative patients develop at least a cellular response that could offer a certain grade of protection against SARS‐CoV‐2. To answer this question, we prospectively studied 148 recipients of either kidney (133) or kidney‐pancreas (15) grafts with assessment of IgM/IgG spike (S) antibodies and ELISpot against the nucleocapside (N) and the S protein at baseline and 2 weeks after receiving the second dose of the mRNA‐1273 (Moderna) vaccine. At baseline, 31 patients (20.9%) had either IgM/IgG or ELISpot positivity and were considered to be SARS‐CoV‐2‐pre‐immunized, while 117 (79.1%) patients had no signs of either cellular or humoral response and were considered SARS‐CoV‐2‐naïve. After vaccination, naïve patients who developed either humoral or cellular response were finally 65.0%, of which 29.9% developed either IgG or IgM and 35.0% S‐ELISpot positivity. Factors associated with vaccine unresponsiveness were diabetes and treatment with antithymocytes globulins during the last year. Side effects were consistent with that of the pivotal trial and no DSAs developed after vaccination. In conclusion, mRNA‐1273 SARS‐CoV‐2 vaccine elicits either cellular or humoral response in almost two thirds of KTRs.